Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies Amends Credit Agreement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life Technologies disclosed in a filing with the US Securities and Exchange Commission today that it has amended and restated its Nov. 21, 2008 credit agreement.

The credit agreement was initially inked immediately following the completion of the merger of Invitrogen and Applied Biosystems to form Life Technologies. That agreement provided a revolving credit facility of $250 million, as well as loan facilities used to help pay for the acquisition of Applied Biosystems and repay other debt.

The credit agreement reported today provides a revolving credit facility of $500 million, under which Life Technologies can borrow funds. The firm said that proceeds from the facility will be used for ongoing working capital and general corporate purposes.

The amended credit facility will terminate on Nov. 21, 2013, at which time all amounts outstanding, plus accrued interest, will be due.

Bank of America is serving as administrative agent, swing line lender, and L/C issuer, the firm said in the SEC filing.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.